Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 143


Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis.

Bowering K, Rodbard HW, Russell-Jones D, Bode B, Harris S, Piletic M, Heller S, Woo V, Babu V, Dethlefsen C, Mathieu C.

Diabetes Ther. 2018 Dec 13. doi: 10.1007/s13300-018-0553-7. [Epub ahead of print]


Patient power - Kidd Gloves.

Burge A, Green M, Russell-Jones D.

Clin Med (Lond). 2018 Oct;18(5):437. doi: 10.7861/clinmedicine.18-5-437. No abstract available.


Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance.

Whyte MB, Shojaee-Moradie F, Sharaf SE, Jackson NC, Fielding B, Hovorka R, Mendis J, Russell-Jones D, Umpleby AM.

J Clin Endocrinol Metab. 2019 Feb 1;104(2):359-368. doi: 10.1210/jc.2018-01176.


SGLT2 inhibitors in Type 1 diabetes: is this the future?

Herring R, Russell-Jones DL.

Diabet Med. 2018 Dec;35(12):1642-1643. doi: 10.1111/dme.13791. No abstract available.


Novel diabetes subgroups.

Feher MD, Munro N, Russell-Jones D, de Lusignan S, Khunti K.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):439. doi: 10.1016/S2213-8587(18)30126-8. No abstract available.


Lessons for modern insulin development.

Herring R, Russell-Jones DDL.

Diabet Med. 2018 Oct;35(10):1320-1328. doi: 10.1111/dme.13692. Epub 2018 Jun 15. Review.


Relationship between islet autoantibody status and the clinical characteristics of children and adults with incident type 1 diabetes in a UK cohort.

Bravis V, Kaur A, Walkey HC, Godsland IF, Misra S, Bingley PJ, Williams AJK, Dunger DB, Dayan CM, Peakman M, Oliver NS, Johnston DG; ADDRESS-2 Management Committee, Patient Advocate Group and Investigators.

BMJ Open. 2018 Apr 4;8(4):e020904. doi: 10.1136/bmjopen-2017-020904.


Fecal Enterobacteriales enrichment is associated with increased in vivo intestinal permeability in humans.

Pedersen C, Ijaz UZ, Gallagher E, Horton F, Ellis RJ, Jaiyeola E, Duparc T, Russell-Jones D, Hinton P, Cani PD, La Ragione RM, Robertson MD.

Physiol Rep. 2018 Apr;6(7):e13649. doi: 10.14814/phy2.13649.


Response to Comment on Russell-Jones et al. Diabetes Care 2017;40:943-950. Comment on Bowering et al. Diabetes Care 2017;40:951-957.

Bode BW, Bowering K, Russell-Jones D.

Diabetes Care. 2018 Mar;41(3):e29-e30. doi: 10.2337/dci17-0051. No abstract available.


Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.

Mathieu C, Bode BW, Franek E, Philis-Tsimikas A, Rose L, Graungaard T, Birk Østerskov A, Russell-Jones D.

Diabetes Obes Metab. 2018 May;20(5):1148-1155. doi: 10.1111/dom.13205. Epub 2018 Feb 4.


Identification of barriers to insulin therapy and approaches to overcoming them.

Russell-Jones D, Pouwer F, Khunti K.

Diabetes Obes Metab. 2018 Mar;20(3):488-496. doi: 10.1111/dom.13132. Epub 2017 Nov 22. Review.


Liraglutide and Renal Outcomes in Type 2 Diabetes.

Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators.

N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.


A UK Civil Aviation Authority protocol to allow pilots with insulin-treated diabetes to fly commercial aircraft.

Mitchell SJ, Hine J, Vening J, Montague J, Evans S, Shaw KM, Frier BM, Heller SR, Russell-Jones DL.

Lancet Diabetes Endocrinol. 2017 Sep;5(9):677-679. doi: 10.1016/S2213-8587(17)30264-4. No abstract available.


Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group.

N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12.


Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting.

Russell-Jones D, Heller SR, Buchs S, Sandberg A, Valentine WJ, Hunt B.

Diabetes Obes Metab. 2017 Dec;19(12):1773-1780. doi: 10.1111/dom.13026. Epub 2017 Jul 25.


Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).

Russell-Jones D, Bode BW, De Block C, Franek E, Heller SR, Mathieu C, Philis-Tsimikas A, Rose L, Woo VC, Østerskov AB, Graungaard T, Bergenstal RM.

Diabetes Care. 2017 Jul;40(7):943-950. doi: 10.2337/dc16-1771. Epub 2017 Mar 29.


Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK.

Bain SC, Feher M, Russell-Jones D, Khunti K.

Diabetes Obes Metab. 2016 Dec;18(12):1157-1166. doi: 10.1111/dom.12760. Epub 2016 Sep 14. Review.


Hepato-preferential insulins: Is this the end, or the end of the beginning?

Russell-Jones DL.

Diabetes Obes Metab. 2016 Nov;18(11):1053-1054. doi: 10.1111/dom.12756. No abstract available.


Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.

Davies MJ, Russell-Jones D, Selam JL, Bailey TS, Kerényi Z, Luo J, Bue-Valleskey J, Iványi T, Hartman ML, Jacobson JG, Jacober SJ; IMAGINE 2 Study Investigators.

Diabetes Obes Metab. 2016 Nov;18(11):1055-1064. doi: 10.1111/dom.12712. Epub 2016 Aug 12.


Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators.

N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.

Supplemental Content

Loading ...
Support Center